Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Study limitation reported by the research below: “Complete response rate and progression-free survival data are not reported in the abstract; only overall response rate is available.”